PDCD1 and melanoma: By assessing the clinical significance of the eEF2K-PD-L1 pathway in PD-1 blockade-treated patients with melanoma, we found that high eEF2K expression could predict a better therapeutic outcome and longer OS time, suggesting eEF2K may be a potential biomarker for the efficacy of PD-1 mAb therapy.